Friday, June 5, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CDC, FDA, NIH workers did not report incidents of political interference, ‘fearing retaliation,’ government watchdog agency says

Just because incidents of political interference within the United States’ top health agencies are not reported, does not mean they don’t happen, a new federal report finds.

The US Government Accountability Office released a report Wednesday detailing how four public health agencies that were reviewed — the US Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institutes of Health and the Office of the Assistant Secretary for Preparedness and Response — do not have procedures in place that define political interference in scientific decision-making. The report also recommends how such incidents of interference should be reported and addressed.

Yet the GAO report notes that employees at the CDC, FDA and NIH have revealed in interviews and via a confidential hotline that they observed incidences they perceived to be political interference but did not report them for various reasons: being unsure how to report the issue, believing that agency leaders already were aware of the incident and fearing retaliation.

“For example, in May 2020, a senior official from ASPR claimed HHS retaliated against him for disclosing, among other things, concerns about inappropriate political interference to make chloroquine and hydroxychloroquine available to the public as treatments for COVID-19,” GAO officials wrote in the report.

Source: CNN

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!